Literature DB >> 15188344

Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer.

Deborah P M Symmons, Alan J Silman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15188344     DOI： 10.1002/art.20312

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  16 in total

Review 1.  Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

Authors:  K L Hyrich; A J Silman; K D Watson; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2004-07-08       Impact factor: 19.103

Review 2.  Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis.

Authors:  Jamie Campbell; David Lowe; Matthew A Sleeman
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

Review 3.  Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies.

Authors:  Silja Rott; Ulrich Mrowietz
Journal:  BMJ       Date:  2005-03-26

4.  Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study.

Authors:  J Askling; L Klareskog; P Blomqvist; M Fored; N Feltelius
Journal:  Ann Rheum Dis       Date:  2006-01-13       Impact factor: 19.103

5.  The age-risk relationship of hematologic malignancies in patients with rheumatoid arthritis: a nationwide retrospective cohort study.

Authors:  Yu-Chih Lin; Hui-Wen Chou; Wen-Chan Tsai; Jeng-Hsien Yen; Shun-Jen Chang; Yi-Ching Lin
Journal:  Clin Rheumatol       Date:  2015-05-20       Impact factor: 2.980

6.  Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort.

Authors:  Francisco Silva; Philip Seo; Darrell R Schroeder; John H Stone; Peter A Merkel; Gary S Hoffman; Robert Spiera; Jodi K Sebastian; John C Davis; E William St Clair; Nancy B Allen; W Joseph McCune; Steven R Ytterberg; Ulrich Specks
Journal:  Arthritis Rheum       Date:  2011-08

7.  [Methotrexate toxicity. Myths and facts].

Authors:  G Keysser
Journal:  Z Rheumatol       Date:  2011-02       Impact factor: 1.372

8.  Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.

Authors:  J Askling; C M Fored; L Brandt; E Baecklund; L Bertilsson; N Feltelius; L Cöster; P Geborek; L T Jacobsson; S Lindblad; J Lysholm; S Rantapää-Dahlqvist; T Saxne; L Klareskog
Journal:  Ann Rheum Dis       Date:  2005-04-13       Impact factor: 19.103

9.  Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events.

Authors:  L Konttinen; V Honkanen; T Uotila; J Pöllänen; M Waahtera; M Romu; K Puolakka; M Vasala; A Karjalainen; R Luukkainen; D C Nordström
Journal:  Rheumatol Int       Date:  2006-01-10       Impact factor: 2.631

Review 10.  Spontaneous remission of "methotrexate-associated lymphoproliferative disorders" after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature.

Authors:  Rita Rizzi; Paola Curci; Mario Delia; Erminia Rinaldi; Antonia Chiefa; Giorgina Specchia; Vincenzo Liso
Journal:  Med Oncol       Date:  2008-05-07       Impact factor: 3.064
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.